In last trading session, Aclaris Therapeutics Inc (NASDAQ:ACRS) saw 0.42 million shares changing hands with its beta currently measuring 0.28. Company’s recent per share price level of $1.16 trading at $0.02 or 1.75% at ring of the bell on the day assigns it a market valuation of $82.66M. That closing price of ACRS’s stock is at a discount of -858.62% from its 52-week high price of $11.12 and is indicating a premium of 49.14% from its 52-week low price of $0.59. Taking a look at company’s average trading volume volume of 833.58K if we extend that period to 3-months.
For Aclaris Therapeutics Inc (ACRS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.78. Splitting up the data highlights that, out of 4 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
Upright in the green during last session for gaining 1.75%, in the last five days ACRS remained trading in the green while hitting it’s week-highest on Monday, 07/01/24 when the stock touched $1.16 price level, adding 8.66% to its value on the day. Aclaris Therapeutics Inc’s shares saw a change of 10.48% in year-to-date performance and have moved 4.04% in past 5-day. Aclaris Therapeutics Inc (NASDAQ:ACRS) showed a performance of 11.54% in past 30-days.
Wall Street analysts have assigned a consensus price target of 25 to the stock, which implies a rise of 95.36% to its current value. Analysts have been projecting 25 as a low price target for the stock while placing it at a high target of 25. It follows that stock’s current price would drop -2055.17% in reaching the projected high whereas dropping to the targeted low would mean a loss of -2055.17% for stock’s current value.
Aclaris Therapeutics Inc (ACRS) estimates and forecasts
Statistics highlight that Aclaris Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 10.48% of value to its shares in past 6 months, showing an annual growth rate of 49.68% while that of industry is 13.90. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 20.67% during past 5 years.
ACRS Dividends
Aclaris Therapeutics Inc is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
